Evolution in the choice of therapies used to treat latrodectism: Redback spider antivenom or standard analgesic medications. Nothing to rave about

Abstract

AbstractObjectivesRedback spider (RBS) antivenom (RBSAV) use appears to have decreased since the results of the RAVE‐2 antivenom efficacy study were released. The aims of this study were to assess change in RBSAV use over time and compare responses to treatment for antivenom and other analgesics.MethodsRetrospective audit of RBS bite referrals to a toxicology unit, from January 2010 to January 2022. Data included demographics, pain severity, treatment (analgesia or RBSAV), response to treatment, re‐presentation rate, adverse events, change in antivenom use over time.ResultsOf 270 presentations, 157 with moderate or severe pain were included (RBSAV n = 51, analgesia n = 106). Median age was 39 years, n = 81 (51%) female. Those receiving antivenom were more likely to report severe pain n = 46/51 (84%) versus n = 68/106 (58%) (P = 0.006). Eighty‐three percent of antivenom doses were administered between 2010 and 2013. Analgesia‐only group received various combinations of paracetamol, NSAIDs, and opioids. In those receiving RBSAV, 17/48 (35%), 26/48 (54%), 5/48 (10%) reported a partial, complete or no reduction in pain, respectively, versus 30/77 (39%), 43/77 (58%) and 4/77 (5%), for analgesia‐only group. Post‐treatment pain was not recorded in three RBSAV and 28 analgesia‐only patients. Pain reduction was no different for intravenous and intramuscular antivenom. Re‐presentation for ongoing pain was more common in the analgesia‐only group, 16/106 (15%) versus 1/51 (2%) for antivenom (P = 0.013).ConclusionAntivenom use fell over the study period. There was no difference in pain relief between RBSAV and analgesia‐only groups. RBSAV, regardless of route of administration, was no better than standard analgesics in pain reduction in the present study.